secwatch.observer — SEC 8-K summary
======================================

Issuer:     Co-Diagnostics, Inc. (CODX)
CIK:        0001692415
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0001493152-24-023796
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Co-Diagnostics files first FDA 510(k) for Co-Dx PCR Pro platform and OTC COVID-19 test
--------------------------------------------------------------------------------

- FDA receives 510(k) submission for Co-Dx PCR Pro instrument and OTC COVID-19 test.
- Company plans to shortly pursue point-of-care (POC) clearance for the same test.
- Other tests in pipeline include tuberculosis, HPV, strep A, and a respiratory multiplex (flu A/B, COVID-19, RSV).
- CEO Dwight Egan says 510(k) clearance would validate the platform and enable commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1692415/000149315224023796/0001493152-24-023796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1692415/000149315224023796/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-023796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer